Funding for this research was provided by:
Received: 19 October 2021
Accepted: 30 December 2021
First Online: 12 January 2022
: The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license number 1071272-159521-PG). The Rotterdam Study Personal Registration Data collection is filed with the Erasmus MC Data Protection Officer under registration number EMC1712001. The Rotterdam Study has been entered into the Netherlands National Trial Register (NTR; ExternalRef removed) and into the WHO International Clinical Trials Registry Platform (ICTRP; ExternalRef removed) under shared catalog number NTR6831. This study was partly performed as part of the Netherlands Consortium of Dementia Cohorts (NCDC), which receives funding in the context of Deltaplan Dementie from ZonMW Memorabel (projectnr 73305095005) and Alzheimer Nederland. All participants provided written informed consent to participate in the study and to have their information obtained from treating physicians.
: Not applicable.
: Dr. M. Arfan Ikram received consulting fees from Biogen Inc. (amount $100–$2000). All other authors declare that they have no competing interests.